Currently, there are three approved treatments for FD in Canada: two enzyme replacement therapies (ERT), agalsidase beta (Fabrazyme) and agalsidase alfa (Replagal), and one oral chaperone therapy, migalastat (Galafold) [6–8]. The gene discussed is GLA; the disease is Fabry disease.